Tofacitinib as an alternative therapy for refractory intestinal Behçet’s syndrome

Jun Zou, Jian-fei Cai, Jing-fen Ye and Jian-Long Guan

Abstract

Background: Intestinal Behçet’s syndrome is a major cause of morbidity and mortality in Behçet’s syndrome.

Objectives: Current treatment challenges remain in refractory intestinal Behçet’s syndrome, when patients failed first and second-line therapies.

Design: We reported the efficacy and safety profiles of tofacitinib in patients with moderate-severe intestinal Behçet’s syndrome in a retrospective single-center study.

Methods: Treatment with glucocorticoids, immunosuppressors, or even anti-TNFα monoclonal antibodies (mAbs) had previously failed. Primary outcomes were clinical remission or low disease activity and endoscopic healing.

Results: We included 13 patients; 11 were administered tofacitinib 5 mg twice daily, and 2 took tofacitinib 5 mg once daily. Nine patients achieved clinical remission after a mean treatment duration of 10.1 ± 7.0 months, and the other four had low disease activity. Follow-up endoscopy was available in 11 patients: 5 had achieved mucosal healing; the other 4 achieved marked mucosal improvement. Prednisone dosage was significantly reduced, from 30 (interquartile range: 20–30) mg/d to 2.5 (interquartile range: 0–12.5) mg/d (p < 0.001). No serious adverse event was observed.

Conclusion: Tofacitinib could be an efficacious and generally well-tolerated option in patients with intestinal Behçet’s syndrome refractory to conventional agents, even anti-TNFα mAbs.

Keywords: anti-TNFα monoclonal antibodies, Behçet’s syndrome, intestinal involvement, refractory, tofacitinib

Received: 3 March 2022; revised manuscript accepted: 16 August 2022.
or gradual loss of response to anti-TNFα mAbs remain high. Accordingly, refractory cases remain a treatment dilemma, particularly non-responder to anti-TNFα mAbs.

Tofacitinib has proved its efficacy in inflammatory disorders like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Compared to anti-TNFα mAbs directed against specific cytokines, JAKi target multiple pathways such as type I interferons (IFNs), interleukin (IL)-6, and IL-23, which have been implicated in the pathogenesis of Behçet’s syndrome. Previously, Liu et al. and our team have reported tofacitinib might be effective in some phenotypes of Behçet’s syndrome, such as vascular, articular, and uveitis involvement. However, intestinal Behçet’s syndrome patients seemed to respond poorly to tofacitinib. So far, no additional data have been reported on the efficacy of tofacitinib in treating intestinal Behçet’s syndrome. Here, we reported the efficacy and safety profiles of tofacitinib in 13 patients with moderate-to-severe intestinal Behçet’s syndrome who were refractory to conventional therapy and even anti-TNFα mAbs.

Patients and methods

Patients

We conducted a retrospective study on patients with intestinal Behçet’s syndrome treated with tofacitinib in the Division of Rheumatology and Immunology at Huadong Hospital, Fudan University, from November 2019 to January 2022. We selected the International Criteria for Behçet’s Disease or the Korean criteria of intestinal Behçet’s syndrome for inclusion. The latter criteria are based on the endoscopic features of ileocolonic ulcerations and systemic manifestations. Patients not fulfilling the criteria were clinically diagnosed with BS based on consensus from gastroenterologists, rheumatologists, pathologists, and endoscopists. This study conforms to the STROBE statement. We have de-identified all patient details.

Exclusion criteria included (1) patients who had been diagnosed with infection, tuberculosis, Crohn’s disease (CD), nonspecific colitis, and drug-induced disease (corticosteroids and non-steroidal anti-inflammatory drugs); (2) patients with impaired cardiac, pulmonary, renal, or hepatic function, neurological disorders, and pregnant or breastfeeding women; and (3) patients with a history of malignancy.

Approach to treatment

Tofacitinib 5 mg was administered twice daily, concurrent treatments with moderate glucocorticoids were allowed, and immunosuppressants were withdrawn.

Clinical measurement

The primary outcomes were clinical remission and low disease activity, with a DAIBD score ≤ 19, and endoscopic healing, defined as mucosal healing. Secondary outcomes included low-disease activity rate determined by DAIBD, endoscopic evaluations, laboratory findings, and any serious adverse events (SAEs) between baseline and last follow-up.

Statistical analysis

Statistical analyses were performed using SPSS version 23.0 (IBM, Armonk, NY, USA). Values are expressed as means ± SD or medians with interquartile range (IQR), according to the data distribution. The student’s test or Wilcoxon signed-rank test was used when appropriate. A p value < 0.05 was considered significant.

Results

Baseline characteristics

Thirteen patients (3 males and 10 females) were analyzed; the mean age was 39.8 ± 4.2 years, and the mean disease duration was 14.9 ± 2.3 years. After enrollment, 11 patients were administered tofacitinib 5 mg twice daily, 2 took tofacitinib 5 mg once daily (according to their body weight), glucocorticoids, and immunosuppressants were withdrawn. The baseline demographic data are shown in Table 1. All patients were refractory to conventional agents; eight were further refractory to anti-TNFα mAbs with a mean number of 2 failed biologics; two patients had a history of surgical resections.
### Table 1. Characteristics and outcomes with tofacitinib therapy in patients with moderate-severe intestinal Behçet’s syndrome.

| Patient | Sex | Age (years) | Duration (years) | Manifestations | Locations of ulceration | Previous surgery | Previous CST, THD, AZA, ADA | Medications on admission | Treatment duration [months] | DAIBD assessment | Endoscopic evaluations |
|---------|-----|-------------|------------------|----------------|------------------------|-----------------|-----------------------------|--------------------------|--------------------------|-------------------|-----------------------|
| 1       | M   | 43          | 5                | RAU, A, EN, PF  | ileocecal ulcer, small intestine | right hemicolectomy | GC, THD, SSZ, CSA, I FX    | GC, THD, SSZ, THD, GC, COL | 2                        | LDA remission    | marked improvement |
| 2       | M   | 18          | 3                | RAU, GU        | ileocecal ulcer, terminal ileum | ileocecal valve, terminal ileum | GC, THD, CSA, ETN, IFX, ADA | THD, SSZ               | 4                        | remission         | marked improvement |
| 3       | F   | 67          | 20               | RAU, GU, A     | ileocecal ulcer, terminal ileum | ileocecal ulcer, terminal ileum | GC, THD, CSA, ETN, IFX, ADA | GC, THD, SSZ, CSA, GC, COL | 18                       | remission         | mucosal healing    |
| 4       | M   | 15          | 5                | RAU, P         | ileocecal ulcer, terminal ileum | ileocecal ulcer, terminal ileum | GC, THD, CSA, ETN, IFX, ADA | GC, THD, SSZ, CSA, GC, COL | 21                       | remission         | mucosal healing    |
| 5       | F   | 40          | 20               | RAU, GU, EN, A | ileocecal ulcer, terminal ileum | ileocecal ulcer, terminal ileum | GC, THD, CSA, ETN, IFX, ADA | GC, THD, SSZ, CSA, GC, COL | 7                        | remission         | mucosal healing    |
| 6       | F   | 40          | 8                | RAU, GU, A     | ileocecal ulcer, terminal ileum | ileocecal ulcer, terminal ileum | GC, THD, CSA, ETN, IFX, ADA | GC, THD, SSZ, CSA, GC, COL | 15                       | remission         | mucosal healing    |
| 7       | F   | 30          | 20               | RAU, EU, P     | ileocecal ulcer, terminal ileum | ileocecal ulcer, terminal ileum | GC, THD, CSA, ETN, IFX, ADA | GC, THD, SSZ, CSA, GC, COL | 14                       | remission         | mucosal healing    |
| 8       | F   | 41          | 15               | RAU, GU, A     | ileocecal ulcer, terminal ileum | ileocecal ulcer, terminal ileum | GC, THD, CSA, ETN, IFX, ADA | GC, THD, SSZ, CSA, GC, COL | 6                        | remission         | mucosal healing    |
| 9       | F   | 66          | 20               | RAU, GU, U, PF | ileocecal ulcer, terminal ileum | ileocecal ulcer, terminal ileum | GC, THD, CSA, ETN, IFX, ADA | GC, THD, SSZ, CSA, GC, COL | 7                        | remission         | mucosal healing    |
| 10      | F   | 46          | 20               | RAU, GU, A     | ileocecal ulcer, terminal ileum | ileocecal ulcer, terminal ileum | GC, THD, CSA, ETN, IFX, ADA | GC, THD, SSZ, CSA, GC, COL | 20                       | remission         | mucosal healing    |
| 11      | F   | 40          | 20               | RAU, GU, A     | ileocecal ulcer, terminal ileum | ileocecal ulcer, terminal ileum | GC, THD, CSA, ETN, IFX, ADA | GC, THD, SSZ, CSA, GC, COL | 20                       | remission         | mucosal healing    |
| 12      | F   | 37          | 20               | RAU, GU, A     | ileocecal ulcer, terminal ileum | ileocecal ulcer, terminal ileum | GC, THD, CSA, ETN, IFX, ADA | GC, THD, SSZ, CSA, GC, COL | 20                       | remission         | mucosal healing    |
| 13      | F   | 43          | 30               | RAU, GU, A     | ileocecal ulcer, terminal ileum | ileocecal ulcer, terminal ileum | GC, THD, CSA, ETN, IFX, ADA | GC, THD, SSZ, CSA, GC, COL | 3                        | LDA remission    | mucosal healing    |
Efficacy of tofacitinib

Mean treatment duration 10.1 ± 1.9 months, DAIBD decreased from 90 (IQR: 75–100) to 10 (IQR: 0–25), \( p = 0.002 \), Figure 1. All patients experienced a rapid and sustained resolution of systemic symptoms, such as fatigue or fever (no. 5 and no. 7), and diminished or resolved abdominal symptoms, such as abdominal pain, constipation, or diarrhea (no. 1–4, 6). C-reactive protein (CRP) dropped from baseline 10.42 (IQR: 2.48–35.35) mg/l to last visit 0.80 (IQR: 0.50–1.28) mg/l, \( p = 0.003 \).

Steroid-sparing effects

At the end of follow-up, tofacitinib 5 mg twice daily was maintained in nine patients, and it was successfully tapered down to 5 mg once daily in four cases. In five patients, corticosteroid was successfully withdrawn, and five other patients received a prednisone dosage of fewer than 10 mg daily. Prednisone dosage was significantly reduced from tofacitinib initiation 30 (IQR: 20–30) mg/d to the last follow-up 2.5 (IQR: 0–12.5) mg/d (\( p < 0.001 \)).

Adverse events

Our study observed no SAEs during tofacitinib therapy, including no cases of herpes zoster, severe infection, cardiovascular event, venous thromboembolic event, and cause of mortality.

Discussion

Our study is the first report indicating the efficacy of tofacitinib in patients with intestinal Behçet’s syndrome, even refractory to anti-TNFα mAbs. We found that tofacitinib therapy was associated with significantly decreased disease activity scores. Within a mean treatment duration of
10 months, most patients (8/13) in our cohort were in remission. They achieved a mucosal healing rate of 55%. Its steroid-sparing effects were observed.

Recently, a meta-analysis of anti-TNFα mAbs in intestinal Behçet’s syndrome combined 13 studies with a total of 739 patients and estimated the pooled proportions of clinical remission at months 3 and 24 were 0.61 (95% CI: 0.48–0.78) and 0.38 (95% CI: 0.16–0.88), and mucosal healing at months 3 and 24 were 0.66 (95% CI: 0.50–0.86) and 0.69 (95% CI: 0.39–1.00), respectively. Although anti-TNFα mAbs are the standard treatment for refractory diseases, the proportion of non-responders remains high. Therapeutic options in cases of failed anti-TNFα mAbs are limited. Our preliminary results imply the efficacy of tofacitinib is comparable to that of tumor necrosis factor inhibitor (TNFi) in intestinal Behçet’s syndrome. Considering most patients in our cohort were TNFi experienced, tofacitinib could have a superior benefit over TNFi.

The treatment options usually overlap between intestinal Behçet’s syndrome and CD. The efficacy of tofacitinib in ulcerative colitis (UC) was not replicated in CD or a previous report with five intestinal Behçet’s syndrome cases. From Liu et al. report, they defined the clinical response as (1) improved: BS-related manifestations resolved and no newly present imaging/endoscopic findings observed and (2) unchanged or worsened: Behçet’s syndrome–related manifestations or abnormal laboratory parameters persisted or worsened after following up for 12–24 weeks. As they mentioned, the intestinal ulceration was healed in one patient and persisted in the other five patients. At the end of the follow-up, four patients had a normal CRP, and two patients had an elevated CRP. However, the authors judged: that 1/6 patients improved, 1/6 worsened, and 4/6 patients were unchanged. Although we do not know the details of endoscopic response in Zhang’s study, we could find some conflicts between Behçet’s Disease Current Activity Form improvement, ESR, CRP levels, and the clinical response judgment. Besides, the high rates of fistula formation (3/6) and perforation (2/6) in Zhang’s study could lead to a poor clinical response.

In our cohort, most patients had features of poor prognosis, such as refractory to conventional treatments, a history of intestinal surgery, or large intestinal ulcers. Tofacitinib, as a pan Janus kinases (JAKs) inhibitor, provided a rapid and broad-spectrum cytokine-blocking effect in patients with intestinal Behçet’s syndrome. As a result, DAIBD scores and levels of CRP decreased substantially, correlated with endoscopic responses. Our results demonstrated the efficacy of tofacitinib in intestinal Behçet’s syndrome patients with large intestinal ulcers. No. 11 patient having a giant ileocecal valve ulcer (5 cm in diameter) achieved mucosal healing after 4 months of treatment.

The limitations of this study arise primarily from an uncontrolled observational design, a small sample size, and a short follow-up duration in several cases. It should be noted that we have more females than males in the cohort, which could lead to a selection bias.

Conclusions
In the present study, our preliminary analysis of tofacitinib administration to patients with refractory intestinal Behçet’s syndrome to conventional agents or even anti-TNFα mAbs demonstrated its high efficacy based on a significant decrease in disease activity index and endoscopy results and its safety profiles. Our data provided a possible application of tofacitinib as an option or rescue therapy in refractory intestinal Behçet’s syndrome to anti-TNFα mAbs. Our encouraging findings justify a more rigorous clinical trial to examine small molecule therapy in treating intestinal Behçet’s syndrome and other phenotypes of Behçet’s syndrome.

Declarations

Ethics approval and consent to participate
The ethics committee approved this study at Huadong Hospital (2016k044), and all participants consented to the treatment.

Consent for publication
Not applicable. All patients details have been de-identified.

Author contributions
Jun Zou: Conceptualization; Data curation; Funding acquisition; Investigation; Writing – original draft; Writing – review & editing.
Jian-fei Cai: Investigation.
Jing-fen Ye: Validation.
Jian-Long Guan: Funding acquisition; Supervision; Writing – review & editing.

Acknowledgements
Thanks, Dr. Da-nian Ji, for kindly providing the endoscopic images.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Natural Science Foundation of China (81871276) and the Clinical research project of Huadong Hospital (HDLC2022010).

Competing interests
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Availability of data and materials
The article’s data will be shared at reasonable request to the corresponding author.

ORCID iD
Jun Zou https://orcid.org/0000-0001-9563-2702

References
1. Zou J, Luo JF, Shen Y, et al. Cluster analysis of phenotypes of patients with Behçet’s syndrome: a large cohort study from a referral center in China. Arthritis Res Ther 2021; 23: 45.
2. Zou J, Shen Y, Ji DN, et al. Endoscopic findings of gastrointestinal involvement in Chinese patients with Behçet’s disease. World J Gastroenterol 2014; 20: 17171–17178.
3. Cheon JH and Kim WH. An update on the diagnosis, treatment, and prognosis of intestinal Behçet’s disease. Curr Opin Rheumatol 2015; 27: 24–31.
4. Jung YS, Cheon JH, Park SJ, et al. Long-term clinical outcomes of Crohn’s disease and intestinal Behçet’s disease. Inflamm Bowel Dis 2013; 19: 99–105.
5. Lee KS, Kim SJ, Lee BC, et al. Surgical treatment of intestinal Behçet’s disease. Yonsei Med J 1997; 38: 455–460.
6. Naganuma M, Iwao Y, Inoue N, et al. Analysis of clinical course and long-term prognosis of surgical and nonsurgical patients with intestinal Behçet’s disease. Am J Gastroenterol 2000; 95: 2848–2851.
7. Tanida S, Inoue N, Kobayashi K, et al. Adalimumab for the treatment of Japanese patients with intestinal Behçet’s disease. Clin Gastroenterol Hepatol 2015; 13: 940–948.e943.
8. Iwata S, Saito K, Yamaoka K, et al. Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet’s disease. Mod Rheumatol 2011; 21: 184–191.
9. Hisamatsu T, Ueno F, Matsumoto T, et al. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet’s disease: indication of anti-TNFα monoclonal antibodies. J Gastroenterol 2014; 49: 156–162.
10. Bao HF, Hou CC, Ye B, et al. Predictors of infliximab refractory intestinal Behçet’s syndrome: a retrospective cohort study from the Shanghai Behçet’s syndrome database. Mod Rheumatol 2021; 2021: roab127.
11. Miyagawa I, Nakano K, Iwata S, et al. Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behçet’s disease. Arthritis Res Ther 2019; 21: 151.
12. Van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. New Engl J Med 2012; 367: 508–519.
13. Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. New Engl J Med 2017; 377: 1537–1550.
14. Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. New Engl J Med 2017; 376: 1723–1736.
15. Puccetti A, Fiore PF, Pelosi A, et al. Gene expression profiling in Behçet’s disease indicates an autoimmune component in the pathogenesis of the disease and opens new avenues for targeted therapy. J Immunol Res 2018; 2018: 4246965.
16. Liu J, Hou Y, Sun L, et al. A pilot study of tofacitinib for refractory Behçet’s syndrome. Ann Rheum Dis 2020; 79: 1517–1520.
17. Zou J, Lin CH, Wang Y, et al. Correspondence on ‘A pilot study of tofacitinib for refractory...
18. International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD). The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity specificity of the new criteria. *J Eur Acad Dermatol Venereol* 2014; 28: 338–347.

19. Cheon JH, Kim ES, Shin SJ, et al. Development and validation of novel diagnostic criteria for intestinal Behçet’s disease in Korean patients with ileocolonic ulcers. *Am J Gastroenterol* 2009; 104: 2492–2499.

20. Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet* 2007; 370: 1453–1457.

21. Cheon JH, Han DS, Park JY, et al. Development, validation, and responsiveness of a novel disease activity index for intestinal Behçet’s disease. *Inflamm Bowel Dis* 2011; 17: 605–613.

22. Zhang M, Liu J, Liu T, et al. The efficacy and safety of anti-tumor necrosis factor agents in the treatment of intestinal Behcet’s disease, a systematic review and meta-analysis. *J Gastroenterol Hepatol* 2022; 37: 608–619.